Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality
among highly immunocompromised patients. Authoritative consensus criteria to diagnose …

Invasive pulmonary aspergillosis (IPA) remains difficult to diagnose and to treat. Most
common risk factors are prolonged neutropenia, hematopoietic stem cell or solid organ …

Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The
SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients …

Background Triazole resistance is an increasing problem in invasive aspergillosis (IA).
Small case series show mortality rates of 50%–100% in patients infected with a triazole …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Invasive aspergillosis (IA) is associated with poor outcomes in …

Background. With use of data from the Prospective Antifungal Therapy (PATH) Alliance
registry, we performed this multicenter, prospective, observational study to assess the …

Background. Invasive aspergillosis (IA) is an important cause of morbidity and mortality in
hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. The …

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

In view of the poor outcomes associated with mucormycosis in patients with haematologic
malignancies (HM) and haematopoietic cell transplant recipients, antifungal combinations …

Background. The benefit of the combination of serum galactomannan (GM) assay and
polymerase chain reaction (PCR)–based detection of serum Aspergillus DNA for the early …